PROSPECTIVE TRIAL OF HIGH-DOSE REIRRADIATION USING DAILY IMAGE GUIDANCE WITH INTENSITY-MODULATED RADIOTHERAPY FOR RECURRENT AND SECOND PRIMARY HEAD-AND-NECK CANCER

被引:57
作者
Chen, Allen M. [1 ]
Farwell, D. Gregory [2 ]
Luu, Quang [2 ]
Cheng, Suzan [1 ]
Donald, Paul J. [2 ]
Purdy, James A. [1 ]
机构
[1] Univ Calif Davis, Dept Radiat Oncol, Ctr Canc, Sacramento, CA 95817 USA
[2] Univ Calif Davis, Dept Otolaryngol Head & Neck Surg, Ctr Canc, Sacramento, CA 95817 USA
来源
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2011年 / 80卷 / 03期
关键词
Reirradiation; Image guidance; Head and neck; Recurrent; Tomotherapy; SQUAMOUS-CELL CARCINOMA; COOPERATIVE-ONCOLOGY-GROUP; RADIATION-THERAPY; PHASE-II; CONCURRENT CHEMOTHERAPY; CONFORMAL RADIOTHERAPY; LOCALLY RECURRENT; FINAL REPORT; PACLITAXEL; CISPLATIN;
D O I
10.1016/j.ijrobp.2010.02.023
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: To report a single-institutional experience using intensity-modulated radiotherapy with daily image-guided radiotherapy for the reirradiation of recurrent and second cancers of the head and neck. Methods and Materials: Twenty-one consecutive patients were prospectively treated with intensity-modulated radiotherapy from February 2006 to March 2009 to a median dose of 66 Gy (range, 60-70 Gy). None of these patients received concurrent chemotherapy. Daily helical megavoltage CT scans were obtained before each fraction as part of an image-guided radiotherapy registration protocol for patient alignment. Results: The 1- and 2-year estimates of in-field control were 72% and 65%, respectively. A total of 651 daily megavoltage CT scans were obtained. The mean systematic shift to account for interfraction motion was 1.38 +/- 1.25 mm, 1.79 +/- 1.45 mm, and 1.98 +/- 1.75 mm for the medial lateral, superior inferior, and anterior posterior directions, respectively. Pretreatment shifts of > 3 mm occurred in 19% of setups in the medial lateral, 27% in the superior inferior, and 33% in the anterior posterior directions, respectively. There were no treatment-related fatalities or hospitalizations. Complications included skin desquamation, odynophagia, otitis externa, keratitis, naso-lacrimal duct stenosis, and brachial plexopathy. Conclusions: Intensity-modulated radiotherapy with daily image guidance results in effective disease control with relatively low morbidity and should be considered for selected patients with recurrent and second primary cancers of the head and neck. (C) 2011 Elsevier Inc.
引用
收藏
页码:669 / 676
页数:8
相关论文
共 27 条
[1]   Intensity-modulated radiotherapy with concurrent chemotherapy for previously irradiated, recurrent head and neck cancer [J].
Biagioli, Matthew C. ;
Harvey, Mark ;
Roman, Eloy ;
Raez, Luis E. ;
Wolfson, Aaron H. ;
Mutyala, Subhakar ;
Han, Hyo S. ;
Markoe, Arnold .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2007, 69 (04) :1067-1073
[2]   TOXICITY CRITERIA OF THE RADIATION-THERAPY ONCOLOGY GROUP (RTOG) AND THE EUROPEAN-ORGANIZATION-FOR-RESEARCH-AND-TREATMENT-OF-CANCER (EORTC) [J].
COX, JD ;
STETZ, J ;
PAJAK, TF .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1995, 31 (05) :1341-1346
[3]   Conformal re-irradiation of recurrent and new primary head-and-neck cancer [J].
Dawson, LA ;
Myers, LL ;
Bradford, CR ;
Chepeha, DB ;
Hogikyan, ND ;
Teknos, TN ;
Terrell, JE ;
Wolf, GT ;
Eisbruch, A .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2001, 50 (02) :377-385
[4]   Full-dose reirradiation for unresectable head and neck carcinoma: Experience at the Gustave-Roussy Institute in a series of 169 patients [J].
De Crevoisier, R ;
Bourhis, J ;
Domenge, C ;
Wibault, P ;
Koscielny, S ;
Lusinchi, A ;
Mamelle, G ;
Janot, F ;
Julieron, M ;
Leridant, AM ;
Marandas, P ;
Armand, JP ;
Schwaab, G ;
Luboinski, B ;
Eschwege, F .
JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (11) :3556-3562
[5]  
Doemer A, INT J RAD O IN PRESS
[6]  
Forastiere AA, 1998, CANCER, V82, P2270, DOI 10.1002/(SICI)1097-0142(19980601)82:11<2270::AID-CNCR24>3.3.CO
[7]  
2-Q
[8]   Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): An intergroup trial of the eastern cooperative oncology group [J].
Gibson, MK ;
Li, Y ;
Murphy, B ;
Hussain, MHA ;
DeConti, RC ;
Ensley, J ;
Forastiere, AA .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (15) :3562-3567
[9]   Re-irradiation with concomitant chemotherapy of unresectable recurrent head and neck cancer: A potentially curable disease [J].
Haraf, DJ ;
Weichselbaum, RR ;
Vokes, EE .
ANNALS OF ONCOLOGY, 1996, 7 (09) :913-918
[10]   STEREOTACTIC BODY RADIOTHERAPY FOR RECURRENT SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK: RESULTS OF A PHASE I DOSE-ESCALATION TRIAL [J].
Heron, Dwight E. ;
Ferris, Robert L. ;
Karamouzis, Michalls ;
Andrade, Regiane S. ;
Deeb, Erin L. ;
Burton, Steven ;
Gooding, William E. ;
Branstetter, Barton F. ;
Mountz, James M. ;
Johnson, Jonas T. ;
Argiris, Athanassios ;
Grandis, Jennifer R. ;
Lai, Stephen Y. .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2009, 75 (05) :1493-1500